Latest

AI in Pharma H1 2026 Report: Mega-Deals, On-Premise Supercomputer Factories, and Clinical Translation Milestones ◆ Using LLMs Safely in Pharma: The Employee Guide to Risk Mitigation, Ethics, and GxP Compliance ◆ US Pharmaceutical Tariffs Update: Policy Realities, The Stockpile 'Unwind', and Ireland’s Strategic Position ◆ US Biopharma Group Pfanstiehl Acquires Nestlé’s Former Askeaton Infant Formula Site in Landmark Mid-West Industrial Transition ◆ ChatGPT Maker OpenAI Selects Dublin Docklands for New European HQ Expansion ◆ After the Mother of All Deals: A Blueprint for the Ireland-India Pharmaceutical Corridor Under the EU-India FTA ◆ AI in Pharma H1 2026 Report: Mega-Deals, On-Premise Supercomputer Factories, and Clinical Translation Milestones ◆ Using LLMs Safely in Pharma: The Employee Guide to Risk Mitigation, Ethics, and GxP Compliance ◆ US Pharmaceutical Tariffs Update: Policy Realities, The Stockpile 'Unwind', and Ireland’s Strategic Position ◆ US Biopharma Group Pfanstiehl Acquires Nestlé’s Former Askeaton Infant Formula Site in Landmark Mid-West Industrial Transition ◆ ChatGPT Maker OpenAI Selects Dublin Docklands for New European HQ Expansion ◆ After the Mother of All Deals: A Blueprint for the Ireland-India Pharmaceutical Corridor Under the EU-India FTA ◆

Search Results

Found 3 results for "neurology" across articles, medicines, trials, companies and the glossary

A Biotech Buying Frenzy: Inside the H1 2026 Pharma M&A Surge

A Biotech Buying Frenzy: Inside the H1 2026 Pharma M&A Surge

An in-depth analysis of the massive wave of pharmaceutical mergers and acquisitions in the first half of 2026, driven by patent cliffs, pipeline replenishment, and high-growth therapeutic areas.

LinkedIn for Medical Science Liaisons (MSLs): The Complete Guide to Showcasing Scientific Expertise Without Violating Compliance

LinkedIn for Medical Science Liaisons (MSLs): The Complete Guide to Showcasing Scientific Expertise Without Violating Compliance

A step-by-step compliance-safe LinkedIn guide exclusively for Medical Science Liaisons. Covers profile optimisation, what to post, what never to post, KOL engagement, off-label rules, digital medical affairs strategy, and how to build scientific credibility on LinkedIn without breaching pharmaceutical regulatory guidelines.

Eisai Allocates £48M to UK Cold-Chain Pharma Packaging Hub

Eisai Allocates £48M to UK Cold-Chain Pharma Packaging Hub

Japanese pharmaceutical company Eisai announces a £48 million investment at its Hatfield, UK site to establish advanced cold-chain supply and packaging capabilities, supported by the Life Sciences Innovative Manufacturing Fund.